Pfizer (PFE) Cash from Investing Activities (2009 - 2026)

Pfizer has disclosed Cash from Investing Activities across 18 years of filings, most recently posting $785.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 76.02% year-over-year to $785.0 million; the TTM figure through Mar 2026 stood at -$3.8 billion (down 127.66% YoY), while the FY2025 annual figure was -$1.4 billion, down 150.94% from the prior year.
• Cash from Investing Activities rose to $785.0 million in Q1 2026, from -$6.1 billion in the prior quarter.
• Over the last five years, Cash from Investing Activities for PFE reached as high as $4.6 billion in Q2 2024 and fell as low as -$25.5 billion in Q3 2023.
• The 5-year median for Cash from Investing Activities is $785.0 million (2026), against an average of -$3.0 billion.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 484.66% — and 2025, when it plunged 156.84%.
• A 5-year view of Cash from Investing Activities shows it stood at -$11.4 billion in 2022, then advanced by 3.31% to -$11.0 billion in 2023, then surged by 138.88% to $4.3 billion in 2024, then plunged by 243.77% to -$6.1 billion in 2025, then soared by 112.77% to $785.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $785.0 million, -$6.1 billion, and -$2.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.